Clinical Trial Update: Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial of fludarabine, bortezomib (Velcade), and rituximab for relapsed or refractory follicular lymphoma has been terminated, with results posted in 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Fludarabine (Fludarabine)
• Rituximab (rituximab)
• Velcade (bortezomib)

Snippet

Sponsor: Hoosier Cancer Research Network | Conditions: Lymphoma, Non-Hodgkin | Phase 2 | Status: TERMINATED | Results posted: 2016-10-24